Bioretec Oy
The answer first
Does Bioretec beat the market?
No, Bioretec has not beaten the market over the last year.
The ranking · Quality, value and trend combined
Better than 28% of Nordic stocks
- Quality50
- Value27
- Trend44
No. 110 of 195 in healthcare
Max for seven days
Follow Bioretec with AuroraAurora lets you know at the next report. No card.
Both with dividends. Figures as of 18 November 2026. General analysis, not personal advice.
Follow your thesis
Ask Aurora about Bioretec
Your first answer is free, no account needed.
Do you own Bioretec, or are you thinking about it?
See it next to the rest of your portfolio, or build your first one with Bioretec and a few more. Free, no card.
Super Stock+44.6%In short
- Bioretec has fallen 97.2% over the past year, including dividends.
- Overall, Bioretec ranks better than 28% of Nordic stocks on quality, value and trend.
- The largest fall over the past three years was 99.6%. The price is 99.3% below its peak now.
What do analysts think of Bioretec?
Quality, value and trend
Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.
Quality, value and trend together. Better than 28% of Nordic stocks.
No. 110 of 195 in healthcare
Medium An average company: the accounts are neither especially strong nor weak.
No. 132 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50
- Debt to equityBorrowings divided by equity0.01
- Asset turnoverSales divided by everything the company owns0.14
- Return on equityProfit divided by equity−44.5%
- Cash conversionOperating cash flow divided by profit–
The ranking is built on equity ratio, ROA and how steadily profit grows.
Low High price: buyers pay a lot today, often because they expect growth.
No. 79 of 197 in healthcareTypical in healthcare: 20Typical in the Nordics: 50
- P/BPrice divided by equity1.6
- P/SPrice divided by sales10.0
- P/EPrice divided by earningsnegative earnings
- P/CFPrice divided by operating cash flownegative earnings
The ranking is built on P/E, P/B and P/S.
Medium The share price has moved about like most stocks over the last year.
No. 77 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50
- 3 months+4.7%
- 6 months+3.7%
- 9 months−92.5%
- 12 months−97.2%
The ranking is built on 3, 6 and 12–1 months.
Return and risk
Return with dividends reinvested.
About Bioretec
Bioretec Oy is a company in healthcare, listed on Nasdaq Helsinki. The share trades in EUR.
Bioretec Oy, a medical device company, develops, manufactures, and markets bioresorbable orthopedic implants for the repair of bone and soft tissue injuries in children and adults worldwide. The company offers Activa IM-Nail, a bioabsorbable option for pediatric forearm intramedullary nailing; ActivaNail, an implant that is be used in upper or lower limbs to ensure successful bone regeneration; ActivaPin, a bioabsorbable implant for upper and lower limb fractures; and ActivaScrew, an absorbable surgical implant that is used in fracture treatment, osteotomy, arthrodesis, and bone graft surgery.


See the full analysis of Bioretec.
The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.
Free forever · No card